logo
Home >
News
> Company News About GMP Intelligent Filling Solution to Accelerate Upgrades in the Cosmeceutical and Biopharmaceutical Industries 

GMP Intelligent Filling Solution to Accelerate Upgrades in the Cosmeceutical and Biopharmaceutical Industries 

2018-08-22

Latest company news about GMP Intelligent Filling Solution to Accelerate Upgrades in the Cosmeceutical and Biopharmaceutical Industries 

Market Trends and Industry Pain Points


As the global cosmeceutical injectable market size is expected to surpass $8.5 billion by 2025, the demand for hyaluronic acid, collagen, and exosome-based products has surged. However, the industry faces two major challenges: 


○    Insufficient aseptic filling efficiency: Traditional production lines struggle to meet the demands for high-end cosmeceutical products requiring small batches and multiple production runs. 
○    Increased regulatory risks: The FDA and EMA have tightened their requirements for traceability in biopharmaceutical production. Over 60% of companies have received audit warnings due to deficiencies in electronic batch records (2024 industry white paper data). 

✅ Ultra-Precise Filling Control 
○    Utilizes nitrogen-protected filling technology, ensuring oxygen levels ≤0.5 ppm to maintain the activity of temperature-sensitive components such as hyaluronic acid and peptides (test data: 92% reduction in degradation rate). 
○    Dynamic weighing system achieves ±0.3% filling accuracy, accommodating vials and ampoules from 1ml to 50ml. 


✅ End-to-End Digital Management 
○    Integrated MES (Manufacturing Execution System) for real-time tracking of production data (temperature, pressure, microbial load) and automated generation of FDA 21 CFR Part 11-compliant electronic records. 
○    QR code traceability module links raw material batches, production personnel, and sterilization parameters, enabling full lifecycle management for regenerative medicine products. 


Industry Application Scenarios
Dermal Filler Injections 
○    Integrated production line for cross-linked hyaluronic acid gel and recombinant collagen lyophilized powder, with a daily capacity of 200,000 units (1ml format). 
○    Case Study: A Korean client achieved a 35% OEE improvement in their Botulinum Toxin production line.

Cell Therapy Products 
○    Closed filling environment (Class 100 cleanroom) ensures the sterility of stem cell culture media and exosome solutions, with viral inactivation validation achieving a SAL of 10^-6. 
Certifications and Service Network 
○    Global Compliance: Meets GMP (2023 Edition), ISO 13485, and PIC/S standards, supporting market entry into Europe, North America, and the Asia-Pacific region. 
○    Localized Support: Technical centers established in Middle East and Southeast Asia provide 72-hour emergency response and process validation services.